• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Vicore Pharma Holding

12.22 SEK-4.23 %13.7, 17.29
Less than 1K followers

VICO

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-4.23 %
+15.50 %
+22.57 %
+0.66 %
+8.14 %
+60.79 %
-17.48 %
-39.33 %
+141.98 %

Vicore Pharma Holding operates in the pharmaceutical industry and focuses on the development of innovative treatments for pulmonary and cardiovascular diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Vicore Pharma was founded in 2000 and is headquartered in Gothenburg, Sweden.

Read more
Market cap
3.44B SEK
Turnover
5.35M SEK
Revenue
3.82M
EBIT %
-11,851.87 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
21.8
2026

Interim report Q2'26

5.11
2026

Interim report Q3'26

25.2
2027

Annual report '26

Press release07.07.2026, 08.00

Vicore Pharma to Participate in the Leerink Therapeutics Forum

Vicore Pharma Holding
Press release06.07.2026, 08.00

Vicore Pharma Appoints Rob Slack as Chief Scientific Officer

Vicore Pharma Holding
Press release01.07.2026, 22.01

Vicore Pharma to Commence Trading in the United States on The Nasdaq Stock Market

Vicore Pharma Holding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release02.06.2026, 08.00

Vicore Pharma to Host Webcast to Discuss Buloxibutid and the Evolving IPF Treatment Landscape

Vicore Pharma Holding
Press release26.05.2026, 08.00

Vicore Pharma to Present at the Jefferies Global Healthcare Conference

Vicore Pharma Holding
Press release22.05.2026, 14.38

Vicore Pharma Pursues US Dual Listing, Files Registration Statement with the SEC

Vicore Pharma Holding
Press release07.05.2026, 08.00

Vicore Pharma Elects Peter Guenter to its Board of Directors

Vicore Pharma Holding
Regulatory press release06.05.2026, 16.30

Announcement from the Annual General Meeting of Vicore Pharma Holding AB (publ)

Vicore Pharma Holding
Regulatory press release06.05.2026, 08.00

Interim Report January – March 2026

Vicore Pharma Holding
Press release29.04.2026, 08.00

Vicore Pharma Announces Presentations at the 2026 American Thoracic Society International Conference

Vicore Pharma Holding
Press release22.04.2026, 08.00

Vicore Pharma Completes Enrollment in the Phase 2b ASPIRE Trial of Buloxibutid in Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding
Regulatory press release01.04.2026, 09.00

NOTICE OF ANNUAL GENERAL MEETING IN VICORE PHARMA HOLDING AB (PUBL)

Vicore Pharma Holding
Regulatory press release26.03.2026, 08.00

Vicore publishes the Annual Report for 2025

Vicore Pharma Holding
Press release09.03.2026, 08.00

Vicore Pharma to Present at Upcoming Investor Conferences

Vicore Pharma Holding
Press release05.03.2026, 08.00

Vicore Pharma Elevates Leadership Team Ahead of Key Clinical and Corporate Milestones

Vicore Pharma Holding
Regulatory press release27.02.2026, 08.00

Year-end report 2025

Vicore Pharma Holding
Press release26.02.2026, 08.00

Vicore Pharma to Present at Upcoming Investor Conferences

Vicore Pharma Holding
Press release18.02.2026, 08.00

Vicore Pharma to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Vicore Pharma Holding
Press release07.01.2026, 08.00

Vicore Pharma to present at the 44th Annual J.P. Morgan Healthcare Conference

Vicore Pharma Holding
Press release19.12.2025, 08.00

Vicore Pharma to move to the Nasdaq Stockholm Mid Cap segment

Vicore Pharma Holding